Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients

Kidney and Blood Pressure Research

Volumn 28, Issue 4, 2005, Pages 218-225

  Reischig, Tomáš ^a   Opatrný Jr , Karel ^a   Třeška, Vladislav ^a   Mareš, Jan ^a   Jindra, Pavel ^a   Švecová, Miroslava ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytomegalovirus prophylaxis; Ganciclovir; High risk recipient; Valacyclovir

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROLOGY; SURGICAL PATIENT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; VALINE; VIREMIA;

EID: 30044438517     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087129     Document Type: Article

References (31)

1. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH: The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997;103:106-113.
2. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850-856.
3. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Matas AJ: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999;68:1879-1883.
4. Humar A, Gillingham K, Payene WD, Sutherland DER, Matas AJ: Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000;70:310-313.
5. Kalil RSN, Hudson SL, Gaston RS: Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant 2003;3:79-81.
6. Legendre CM, Norman DJ, Keating MR, Maclaine GDH, Grant DM: Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000;70:1463-1468.
7. Schnitzler MA, Loell JA, Hmiel SP, Hardinger KL, Liapis H, Ceriotti CS, Brennan DC: Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003;14:780-785.
8. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-1751.
9. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H, Rubin RH: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
10. Reinke P, Prosch S, Kern F, Volk HD: Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999;1:157-164.
11. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mis-matched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-1464.
12. Isenberg A, Shen GK, Singh TP, Hahn A, Conti DJ: Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy. Clin Transplant 2000;14:193-198.
13. Isada CM, Yen-Lieberman B, Lurain NS, Schilz R, Kohn D, Longworth DL, Taege AJ, Mossad SB, Maurer J, Flechner SM, Mawhorter SD, Braun W, Gordon SM, Schmitt SK, Goldman M, Long J, Haug M, Avery RK: Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002;4:189-194.
14. Limaye AP, Corey L, Koelle DM, Davis CN, Boeckh M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-649.
15. Brennan DC, Garlock KA, Singer GG, Schnitzler MA, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Shenoy S, Howard TK, Storch GA: Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997;64:1843-1846.
16. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-1470.
17. Cole NL, Balfour HH Jr: In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-261.
18. Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC: A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998;66:1682-1688.
19. Reischig T, Jindra P, Mares J, Cechura M, Svecova M, Hes O, Opatrny K Jr, Treska V: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005;79:317-324.
20. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML: Pharmacokinetics of acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
21. Brennan DC, Garlock KA, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Miller SB, Shenoy S, Howard TK, Storch GA: Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1996;8:118-125.
22. Racusen LC, Solez K, Colvin RB, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723.
23. Ljungman P, Plotkin SA: Workshop on CMV disease; definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995;99(suppl):87-89.
24. Singh N: Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001;32:742-751.
25. Patel R, Paya CV: Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
26. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-1387.
27. Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, Gohh R: Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrol Dial Transplant 2003;18:809-813.
28. Winston DJ, Yeager M, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-758.
29. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
30. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Ney AL, Odland MD, Rao VK: Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989;149:2733-2736.
31. Reddy SP, Handa A, Tan L, Devaney A, Hughes D, Mason P, Friend PJ, Darby CL: Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. Transplant Int 2003;16:726-729.